# Chiral Quest

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/chiral-quest

- Industry: Pharmaceuticals
- Headquarters: Suzhou, China
- Website: www.chiralquest.com
- Total disclosed funding: $36M
- Latest round: Series C (Jun 24, 2013)
- Investors on record: 6

## About

Chiral Quest is a specialized company focusing on the development and production of chiral pharmaceuticals using innovative asymmetric catalytic hydrogenation technology.Founded in 2000 and headquartered in Suzhou, China, Chiral Quest develops chiral pharmaceuticals and key intermediates. The CEO, Shengwen Wu, leads the company, which has participated in 4 funding rounds, with the latest being a Series C round in which they raised USD 23.00 mn, bringing the total raised to USD 23.00 mn. Investors in this round included China Renaissance Capital Investment, Infinity Group, Kaiwu Capital, Kleiner Perkins, and Oriza Holdings.CHIRAL Body specializes in chiral pharmaceuticals and key intermediates, utilizing proprietary asymmetric catalytic hydrogenation technology. Their offerings include various chiral drug molecules produced through environmentally friendly processes, serving global pharmaceutical companies like Pfizer, Merck, and Lonza. Additionally, they provide custom research and development services for specific client needs in both China and international markets, particularly Europe and North America.CHIRAL Body’s revenue primarily stems from B2B partnerships with multinational pharmaceutical firms for active pharmaceutical ingredients and advanced intermediates. Contracts are generally structured around long-term supply agreements or customized production agreements based on client specifications and product complexity, emphasizing tailored R&D and production capabilities that meet high-quality standards.Chiral Quest aims to expand its portfolio with new chiral products planned for launch in the upcoming year. The company is also strategizing to penetrate new markets, particularly focusing on Europe and North America by the end of 2024. The recent funding from the Series C round will support these initiatives, allowing for enhanced development capabilities and market outreach, particularly following the sale of Kaiwu Capital's stake in the company.

## Funding rounds

- Series C, Jun 24, 2013, $23M — Kleiner Perkins, Infinity Group, China Renaissance Capital Investment, Oriza Holdings, Kaiwu Capital
- Series B, Dec 2, 2008, $13M — Kleiner Perkins, Infinity Group, Japan Asia Investment Company

## Investors

- Kleiner Perkins (https://capitalatlas.ai/funds/kleiner-perkins) — Series B, Series C
- Infinity Group (https://capitalatlas.ai/funds/infinity-group) — Series B, Series C
- Japan Asia Investment Company (https://capitalatlas.ai/funds/japan-asia-investment-company) — Series B
- China Renaissance Capital Investment (https://capitalatlas.ai/funds/china-renaissance-capital-investment) — Series C
- Oriza Holdings (https://capitalatlas.ai/funds/oriza-holdings) — Series C
- Kaiwu Capital (https://capitalatlas.ai/funds/kaiwu-capital) — Series C